Skip to content
thestock.space

On 6 Nov 2026, Biocon was priced at ₹365.10, or 122.5× trailing earnings, against an industry P/E of 49.1×, and the shares are 18% below their 52-week high. It earns ROCE of 2.8% and ROE of 1.0%, and sales grew 15% a year over 3 years while net profit fell 5.9%. Its dividend yield is 0.1%, and debt is 0.42× equity. It is a mid-cap company with a market cap of ₹59,794 Cr, the largest of 20 Biotechnology companies by market cap; the shares fell 4.9% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹360.00
Day high
₹365.90
Day low
₹357.35
Prev. close
₹362.00
Volume
51.2 L

Health check

1 good · 5 to check
  • ReturnsAhead

    −4.9% over a year, better than 5 of 7 peers.

  • Price tagPricier

    P/E 122.5 vs industry 49.1.

  • GrowthSlow

    Sales +15.3%, profit −5.9% a year over 3 years.

  • ProfitabilityWeak

    ROCE 2.8% vs peer median 16.7%.

  • Balance sheetStretched

    Debt 0.42× equity, interest covered 1.5×, Piotroski 7 of 9.

  • Red flags3 to check

    Return on equity is low at 1.0%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Biotechnology

19 listed peers. Screen the industry

Mid cap

₹59,794 Cr, the largest of 20 in its industry.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Sep 2026: sales ₹17,331 Cr · profit ₹452 Cr
Market cap
₹59,794 Cr
Mid cap
P/E
122.5
Industry 49.1
Price to book
1.73
Peers 4.68
Dividend yield
0.14%
ROE
1.0%
Peers 14.3%
ROCE
2.8%
Peers 16.7%
Debt to equity
0.42
Debt ₹15,698 Cr
EPS (TTM)
₹2.98
Face value ₹5
OPM (TTM)
19.4%
Net margin 2.6%
Sales growth
+1.9%
Latest quarter vs a year ago
Profit growth
−51.1%
Latest quarter vs a year ago
Price to sales
3.45
EV/EBITDA 21.5

Strengths and risks

Strengths

  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • Return on equity is low at 1.0%.
  • Quarterly profit down 51.1% on a year ago.
  • P/E of 122.5 against an industry P/E of 49.1.

Derived automatically from reported figures. Not a recommendation.

About Biocon

Biocon Limited, together with its subsidiaries, manufactures biotechnology products and offers research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics; Biosimilars; and Contract Research, Development and Manufacturing Organization (CRDMO) segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, central nervous system,…

Headquarters
Bengaluru
Employees
16,447
Sector
Healthcare
ISIN
INE376G01013
Website
biocon.com

Price range

52 weeks

₹318.40₹447.15

Today

₹357.35₹365.90
Avg volume (3M)
31.1 L
1-year return
minus 4.9%
From 52-week high
minus 18.3%

Analyst consensus

19 analysts
BuyMean target ₹437.26 plus 19.8%

Target range, with today’s price

Low ₹326.00High ₹534.00

Next results expected around 4 Feb 2027

Consensus from Yahoo Finance. Not a recommendation.

Peers · Biotechnology

Compare with peersScreen the whole industry
Company
BIOCONBiocon365.10plus 0.86%59,794122.51.732.8%1.0%19.4%15.3%−5.9%0.14%minus 4.9%
ANTHEMAnthem Biosciences915.55plus 0.22%51,59484.615.7426.8%20.4%41.4%26.2%15.4%0.22%plus 30.1%
ONESOURCEOnesource Specialty Pharma1,599.80plus 1.13%18,346–3.100.3%0.0%23.5%232.3%–0.00%minus 13.7%
CONCORDBIOConcord Biotech632.60minus 5.96%13,23647.46.4816.7%14.3%34.5%8.0%2.8%0.60%minus 7.5%
BLUEJETBlue Jet Healthcare553.80minus 3.91%9,60734.54.5224.0%19.9%31.4%9.4%15.7%0.22%minus 5.0%
SUPRIYASupriya Lifescience695.80minus 19.99%5,60028.24.6822.3%19.1%21.4%21.2%32.5%0.14%plus 9.2%
ZOTAZota Health Care1,231.10plus 1.01%4,264–6.82−7.3%−24.1%0.1%56.7%–0.08%minus 21.9%
DCALDishman Carbogen Amcis156.64minus 0.56%2,456152.10.372.7%1.6%16.1%7.5%–0.00%minus 47.1%
Median of 7 peers–−0.56%9,60747.44.6816.7%14.3%23.5%21.2%15.5%0.14%−7.5%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrSep 25Dec 25Mar 26Jun 26Sep 26
4,2634,1734,4844,2924,345
3,4273,5163,4643,4453,514
8356571,020847831
19.6%15.8%22.8%19.7%19.1%
9329352.554.534.5
272210232213240
473515513547564
−11.9−293−80.4−13.5−6.7
171−67.824812854.8
22.5%23.6%19.8%−7.2%−3.5%
84.514412614141.3
0.651.070.790.870.25

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+15.3%
Profit CAGR 3Y
−5.9%
EPS CAGR 3Y
−10.0%
ROE
1.0%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
10,93414,19615,05216,780
–+29.8%+6.0%+11.5%
8,19411,19311,73913,101
2,7403,0033,3133,679
25.1%21.2%22.0%21.9%
−21128.246.7−26.1
419974888965
1,1131,5691,6871,957
−99.81,0371,102−283
8971,5251,887448
28.3%14.9%24.2%17.7%
4631,0231,013386
–+121.0%minus 0.9%minus 61.9%
3.878.548.462.82

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
600600600811
17,26719,18321,04433,221
18,01916,27718,36215,434
16,15720,01018,79114,185
52,04356,07158,79763,651
10,12312,20813,60814,734
2,5884,2164,2954,683
7887547471,440
3,7263,1124,9244,043
34,81935,78135,22338,751
52,04356,07158,79763,651

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
1,8532,9544,0611,994
−14,282−1,005−234−2,082
13,049−2,333−1,854−924
619−3831,973−1,012
−1,726−1,932−2,343−1,912
1261,0221,71882.3
−71.8−203−82.9−90.8

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 32.0% (Yahoo estimate).

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you